Curated News
By: NewsRamp Editorial Staff
October 14, 2026
Retension Prices $45M Upsized IPO to Advance Hypertension Drug
TLDR
- Retension raised $45 million in its upsized IPO, funding a Phase 2b trial for RTN-001 and positioning it to advance in the hypertension market.
- Retension priced 3,750,000 shares at $12 each, granting underwriters a 30-day option for 562,500 more shares, with trading on Nasdaq under RTSN.
- Retension's IPO proceeds will support clinical trials of RTN-001, aiming to bring a new treatment option to patients with uncontrolled hypertension.
- Retension's IPO on Nasdaq raised $45 million to fund a Phase 2b trial of RTN-001, a potential therapy for resistant hypertension.
Impact - Why it Matters
Retension's successful IPO and the funding of its Phase 2b trial for RTN-001 highlight the ongoing need for innovative treatments for uncontrolled hypertension, a condition affecting millions worldwide who do not respond adequately to existing therapies. If RTN-001 proves effective in later-stage trials, it could offer a new option for patients with resistant hypertension, potentially reducing cardiovascular risks and improving outcomes. The listing also provides investors with a new opportunity in the cardiovascular space, where unmet medical needs remain high. Moreover, the involvement of reputable underwriters underscores confidence in the company's approach, which could attract further investment and spur competition in the development of next-generation antihypertensive therapies.
Summary
Retension (NASDAQ: RTSN), a clinical-stage biopharmaceutical company focused on hypertension and cardiovascular diseases, has announced the pricing of its upsized initial public offering. The company is offering 3,750,000 shares of common stock at $12 per share, expecting to raise $45 million in gross proceeds before underwriting discounts, commissions, and other expenses. Retension has also granted underwriters a 30-day option to purchase up to an additional 562,500 shares to cover over-allotments. The shares were expected to begin trading on the Nasdaq Capital Market on October 9, 2026, with the offering scheduled to close on or about October 13, subject to customary closing conditions.
The net proceeds, combined with existing cash and cash equivalents, will primarily fund the completion of a Phase 2b clinical trial of RTN-001 for uncontrolled hypertension and support preparations for a planned Phase 3 trial. Remaining funds will be used for general corporate purposes and operating expenses. Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. are serving as joint bookrunning managers, with Titan Partners as lead manager. The offering aims to accelerate the development of RTN-001, a potential treatment for patients with uncontrolled and resistant hypertension.
The announcement was distributed by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions to help companies reach investors and the public effectively. For more information, visit https://www.retensionpharmaceuticals.com/.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Retension Prices $45M Upsized IPO to Advance Hypertension Drug
